DELIVERY SYSTEMS FOR INTRAOCULAR ROUTES

被引：43

作者：

PEYMAN, GA

GANIBAN, GJ

机构：

[1] LSU Eye Center, Louisiana State University Medical Center School of Medicine, New Orleans, LA 70112-2234, 2020 Gravier St., Suite B

来源：

ADVANCED DRUG DELIVERY REVIEWS | 1995年 / 16卷 / 01期

基金：

美国国家卫生研究院;

关键词：

ACQUIRED IMMUNODEFICIENCY SYNDROME; BIODEGRADABLE IMPLANTABLE DEVICE; CYTOMEGALOVIRUS RETINITIS; ENDOPHTHALMITIS; INTRAVITREAL INJECTION; LIPOSOME; MICROSPHERE; POLYMER; PROLIFERATIVE VITREORETINOPATHY; SUSTAINED RELEASE;

D O I：

10.1016/0169-409X(95)00018-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Intravitreal drug delivery has been developed to treat posterior segment diseases because the blood-ocular barrier prevents treatment by topical, systemic, or subconjunctival routes from attaining therapeutic levels in the vitreous. Endophthalmitis, uveitis, proliferative vitreoretinopathy, and viral retinitis are treated by intravitreal injection. Efforts to sustain drug delivery have included encapsulation of drugs in liposomes (made of lipids) or microspheres (made of polymers). In many instances the drug's toxicity to the retina was reduced and the clearance time was slowed. However, these methods cause clouding of the vitreous and can prolong drug delivery for only one month. Implantable devices have been used, such as an osmotic minipump, a drug pellet coated with polyvinyl alcohol and ethylene vinyl acetate, and polysulfone capillary fiber. Biodegradable devices are under investigation, including a drug matrix and a porous reservoir system, both made of polymers; these devices would not require surgical removal.

引用

页码：107 / 123

页数：17

共 140 条

[11]

McGrand, Post-operative intra-ocular infection, Trans. Ophthalmol. Soc. UK, 88, pp. 223-230, (1968)

[12]

Sugar, Zekman, Late infection of filtering conjunctival scars, Am. J. Ophthalmol., 46, pp. 155-170, (1958)

[13]

Christensen, Robinson, Late infection of filtration blebs, Trans. Pacif. Coast Oto-Ophthalmol. Soc., 44, pp. 95-101, (1963)

[14]

Golden, Coppel, Ocular tissue absorption of gentamicin, Arch. Ophthalmol., 84, pp. 792-796, (1970)

[15]

Keller, Tsao, Chandrasekaran, Hatfield, Ocular kinetics of extended duration fluorometholone (0.1%) formulations vs ointment and aqueous suspension, Invest. Ophthalmol. Vis. Sci., 34, (1993)

[16]

Umemoto, Takahashi, Higashi, Evaluation of ophthalmic suspension containing pilocarpine microcapsules: pharmacodynamic and pharmacokinetic studies, Invest. Ophthalmol. Vis. Sci., 34, (1993)

[17]

Bar-Ilan, Aviv, Friedman, Vered, Belkin, Amselem, Baru, Beilin, Wellner, Wolf, Schwarz, Newmann, Improved performance of ocular drugs formulated in submicron emulsions, Invest. Ophthalmol. Vis. Sci., 34, (1993)

[18]

Espana, Chipont, Sanchez, Romero, Navea, Diaz, Collagen shields enhanced penetration of topical cyclosporin, Invest. Ophthalmol. Vis. Sci., 34, (1993)

[19]

McPherson, Presley, Crawford, Aqueous humor assays of subconjunctival anti-biotics, Am. J. Ophthalmol., 66, pp. 430-435, (1968)

[20]

Clements, Tailor, A study of aqueous and serum levels of ceftazidime following subconjunctival administration, Br. J. Ophthalmol., 71, pp. 433-435, (1987)

← 1 2 3 4 5 6 7 8 9 10 →